Sucampo Pharmaceuticals — Merger or Acquisition (August 2015)
14 slides from Sucampo Pharmaceuticals's merger presentation, Aug 26, 2015
Slide 1: Tender Offer to Acquire R-Tech Ueno
Tender Offer to Acquire R-Tech Ueno August 26, 2015 $ sucampo The Science of Innovation
Slide 2: Forward-Looking Statements
Forward-Looking Statements presentation, e $ sucamPo 2 The Science of Innovation
Slide 3: Important Information for Investors and Shareholders
Important Information for Investors and Shareholders The offer Japan. i ion i i Ff an offer to purchase nor p y securities. e $ sucamPo 3 The Science of Innovation
Slide 4: Acquisition of R-Tech Ueno
Acquisition of R-Tech Ueno offer | e @ SUCAMPO The Science of Innovation
Slide 5: Strategic Benefits
Strategic Benefits y Increased revenues Enhanced profitability Stronger cash flow generation e 2 SUCAMPO 5 he Science of Innovation
Slide 6: 2016 Guidance and Synergies
2016 Guidance and Synergies For FY 2016, i izati ion, expect: e Net income of $55 - $60M e EPS of $1.20 - $1.30 e Adjusted EBITDA of $95M - $100M. e @ SUCAMPO 6 The Science of Innovation
Slide 7: Transaction Highlights
Transaction Highlights ° ¢ 16% premium over * 16% premium over Tender offer 567 f R-Tech U ° 1,900 Japanese yen per share shares ° 1,400 Japanese yen per share e ? SUCAMPO The Science of Innovation
Slide 8: Transaction Timing and Financing
Transaction Timing and Financing Tender offer e Concludes October 13, 2015 e @ SUCAMPO 8 The Science of Innovation
Slide 9: R-Tech Ueno Overview
R-Tech Ueno Overview of AMITIZA p' Takeda e Gastroenterology e Ophthalmology ° e Oncology AMITIZA revenue e Increased 33% YoY Ain Japan ° ~ 25% of FY 2014 sales e ? SUCAMPO The Science of Innovation
Slide 10: Key Drivers
Key Drivers 1. 4 on AMITIZA ° Takeda partners ¢ 10 oY SUCAMPO he Science of Innovation
Slide 11: Target First Indication Development Comments
= — Z Z Target First Indication Develepaient ‘Comments Stage Gl/Metabolic/inflammation EEE Microparticle icp Pediatric functional constipation; adi P3. New liquid-like formulation cu BK2 Retinitis —— PS Financial —— ‘in Japan by AMED- cae SS ae rm Sicampo Program))|_ R-Tech Ueno Program $ SUCAMPO ii
Slide 12: VAP-1 Inhibitor Programs
VAP-1 Inhibitor Programs RTU-1069 (Oral) e NASH, COPD, di i i immune-oncology e Phase 1 SAD completed e Phase 1 MAD is next step RTU-009 (IV) e IND-enabling studies are next step ¢ 12 @ SUCAMPO The Science of Innovation
Slide 13: Conclusion
Conclusion opportunities development-stage products $ suCAMPO 3 @ “The Sclence of Innovation
Slide 14: e ?
e ? SUCAMPO The Science of Innovation
Sucampo Pharmaceuticals — Merger or Acquisition (August 2015) on 6ix